How to Submit
Browse
Events
Communities
About

Targeted Degradation of Oncogenic KRASG12C by VHL-recruiting PROTACs

10 April 2020, Version 1
Working Paper
This content is an early or alternative research output and has not been peer-reviewed by Cambridge University Press at the time of posting.

Abstract

We report the development of LC-2, the first PROTAC capable of degrading endogenous KRASG12C. LC-2 covalently binds KRASG12C with a MRTX849 warhead and recruits the E3 ligase VHL, inducing rapid and sustained KRASG12C degradation leading to suppression of MAPK signaling in both homozygous and heterozygous KRASG12C cell lines. LC-2 demonstrates that PROTAC-mediated degradation is a viable option for attenuating oncogenic KRAS levels and downstream signaling in cancer cells.

Keywords

KRas
PROTAC
Protein Degradation
VHL
E3 Ligase

Supplementary materials

Title
Description
Actions
Title
KRAS Supplemental Figures Final v2
Description
Actions
Title
Supporting Information
Description
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting and Discussion Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.

Now Published

Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs [opens in a new tab]
Michael J. Bond, Ling Chu, Dhanusha A. Nalawansha, Ke Li, Craig M. Crews journal article
ACS Central Science , Volume 6, Issue 8
Online publication date: Jul 08, 2020

Version History

Apr 10, 2020 Version 1

Metrics

11,422
4,106
0
Views
Downloads
Citations

License

CC logo
CC
BY logo
BY
NC logo
NC
ND logo
ND
The content is available under CC BY NC ND 4.0 [opens in a new tab]

DOI

10.26434/chemrxiv.12091176.v1
D O I: 10.26434/chemrxiv.12091176.v1 [opens in a new tab]

Funding

NIH (R35CA197589)
NIH (F31CA232477)
NIH (5T32GM067543)
American Cancer Society Professorship

Author’s competing interest statement

C.M.C is founder, shareholder, and consultant to Arvinas, Inc., which supports research in his laboratory.

Share